Overview
VNRX market data
Price History
VNRX price chart · 1M
- O
- 0.467300
- H
- 0.467300
- L
- 0.327200
- C
- 0.333500
- Vol
- 164,335.00
- Source
- US equities market feed
- Observed
- Aug 26, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $0.47
- Previous Close
- $0.38
- Day High
- $0.47
- Day Low
- $0.33
- 52 Week High
- $6.00
- 52 Week Low
- $0.33
- 7 Day Return
- -29.61%
- 30 Day Return
- -62.10%
- 90 Day Return
- -88.46%
- 1 Year Return
- -91.57%
- Daily Notional Volume
- $54.8K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$4.37 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.16 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -997.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.37 – $14.80 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $6.8M · P/B 9.37 · P/S 2.76.
Company News
Nasdaq Surges 200 Points; Nvidia Posts Upbeat Q2 ResultsBenzinga · Aug 27, 2026, 2:02 PM
Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic ValidationsBenzinga · Aug 27, 2026, 11:35 AM
Why Salesforce Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving PremarketBenzinga · Aug 27, 2026, 9:56 AM
VolitionRx shares are trading lower. The company announced the publication of a peer‑reviewed paper and editorial showing its Nu.Q NETs H3.1 biomarker predicts 28‑day mortality and need for renal replacement therapy in sepsis patients.Benzinga · Aug 26, 2026, 4:23 PM
VolitionRx Reports 112% H1 Revenue Growth, Advances Toward $5M Veterinary MilestoneBenzinga · Aug 26, 2026, 1:22 PM
VolitionRx Announces Publication Of Peer-Reviewed Paper And Editorial Indicating That Its Nu.Q NETs H3.1 Biomarker Is An Independent Predictor Of 28-Day Mortality And Need For Renal Replacement Therapy In Sepsis And Septic Shock PatientsBenzinga · Aug 26, 2026, 12:21 PM
8-K filing — VOLITIONRX LTD (VNRX)SEC EDGAR · Aug 24, 2026, 9:00 PM
VolitionRX Reports Q2 2026 Results: Full Earnings Call TranscriptBenzinga · Aug 14, 2026, 1:29 PM
VolitionRX Q2 EPS $(0.85) Misses $(0.57) Estimate, Sales $398.657K Miss $482.667K EstimateBenzinga · Aug 13, 2026, 8:42 PM
VolitionRx Announces That Results Utilizing Its Lateral Flow Prototype Are Highly Correlated With Results Utilizing Its Legacy Automated Nu.Q® NETs Test In Critically Ill Sepsis PatientsBenzinga · Aug 12, 2026, 12:19 PM